NasdaqGS:RAREBiotechs
Assessing Ultragenyx Pharmaceutical (RARE) Valuation After UX111 FDA Review Acceptance And Growing GTX-102 Optimism
Ultragenyx Pharmaceutical (RARE) is back in focus after the FDA accepted its resubmitted BLA for UX111, assigning a September 19, 2026 PDUFA date, alongside growing institutional interest in the GTX-102 program.
See our latest analysis for Ultragenyx Pharmaceutical.
Even with the fresh regulatory progress on UX111 and growing attention on GTX-102, the stock’s momentum has been weak, with the share price down 17.34% over the past 30 days and the 1-year total shareholder return declining...